Literature DB >> 17520259

Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab.

Boris A Cruz1, Dorothy D Reis, Célia Aparecida A Araujo.   

Abstract

Sarcoidosis is a chronic disease of unknown etiology characterized by granulomatous infiltration of several organs. Up to two- thirds of patients develop ocular inflammation eventually leading to significant visual loss. Treatment includes corticosteroids and immunosuppressive agents, but refractory cases do occur. In this report, the authors describe two patients with multi-systemic sarcoidosis and refractory retinal vasculitis who experienced an excellent response to infliximab. This report emphasizes the importance of TNF-alpha in the pathophysiology of this disease and warrants further studies with anti-TNF therapy in patients with refractory ocular sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17520259     DOI: 10.1007/s00296-007-0359-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  5 in total

1.  Infliximab in sarcoidosis: more answers or more questions?

Authors:  Eric S White
Journal:  Am J Respir Crit Care Med       Date:  2006-10-01       Impact factor: 21.405

2.  A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

Authors:  Eric B Suhler; Justine R Smith; Michael S Wertheim; Andreas K Lauer; Daryl E Kurz; Terri D Pickard; James T Rosenbaum
Journal:  Arch Ophthalmol       Date:  2005-07

3.  Treatment of sarcoidosis with infliximab.

Authors:  John D Doty; Joseph E Mazur; Marc A Judson
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

Review 4.  Sarcoidosis and uveitis.

Authors:  Nicholas P Jones
Journal:  Ophthalmol Clin North Am       Date:  2002-09

5.  Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.

Authors:  Robert P Baughman; Marjolein Drent; Mani Kavuru; Marc A Judson; Ulrich Costabel; Roland du Bois; Carlo Albera; Martin Brutsche; Gerald Davis; James F Donohue; Joachim Müller-Quernheim; Rozsa Schlenker-Herceg; Susan Flavin; Kim Hung Lo; Barry Oemar; Elliot S Barnathan
Journal:  Am J Respir Crit Care Med       Date:  2006-07-13       Impact factor: 21.405

  5 in total
  6 in total

1.  [DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].

Authors: 
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059

2.  [Bilateral recurrent blurred vision associated with halos around sources of light and headache].

Authors:  D Völcker; T Reinhard; T Ness
Journal:  Ophthalmologe       Date:  2012-04       Impact factor: 1.059

3.  Brainstem Infarction and Panuveitis due to Sarcoidosis Successfully Treated with Steroid Pulse Therapy.

Authors:  Natsuyo Yoshida-Hata; Shigeko Yashiro; Noritoshi Arai; Sousuke Takeuchi
Journal:  Case Rep Med       Date:  2012-02-08

Review 4.  Informed consent and biological agents in rheumatology and internal medicine.

Authors:  Gabriele Mandarelli; Florenzo Iannone; Stefano Ferracuti; Ignazio Grattagliano; Marcello Benevento; Biagio Solarino; Davide Ferorelli; Roberto Catanesi
Journal:  Eur J Clin Invest       Date:  2022-05-18       Impact factor: 5.722

5.  A case series of refractory cutaneous sarcoidosis successfully treated with infliximab.

Authors:  Papapit Tuchinda; Matthew Bremmer; Anthony A Gaspari
Journal:  Dermatol Ther (Heidelb)       Date:  2012-07-26

Review 6.  Ischemic retinal vasculitis and its management.

Authors:  Lazha Talat; Sue Lightman; Oren Tomkins-Netzer
Journal:  J Ophthalmol       Date:  2014-04-15       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.